CENTOGENE

The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

H.C. Wainwright 24th Annual Global Investment Conference

CENTOGENE NV (NASDAQ: CNTG)

September 12, 2022 - New York

Presenter: Kim Stratton, CEO

Safe Harbour and Disclaimer Statement

This presentation has been prepared by CENTOGENE N.V. (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project" or "expect," "may," "will," "would," "could" or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

Essential Life Science Partner in Rare and Neurodegenerative Diseases



CENTOGENE

- Largest Real-World Data Repository for Rare & Neuro Diseases
- Broadest diagnostic testing portfolio for rare diseases
- Accelerate & De-risk from discovery to market access

Insights to 2,500 Rare and Neurodegenerative to Support Breakthrough Therapies



CENTOGENE

- Largest Real-World Data Repository for Rare & Neuro Diseases
- Broadest diagnostic testing portfolio for rare diseases
- Accelerate & De-risk from discovery to market access

Opportunity: By 2024, 18% of Rx Worldwide Expected to Target Rare Diseases

Significant Need Rare Diseases

- ~350 million people affected by rare genetic diseases, ~90% undiagnosed
- Estimated 80% of ~7,000 rare diseases are genetic in origin: ~5,600[1]
- Public datasets are ~80% of European descent[2]
- <5% of rare diseases have meaningful therapies

Growing Market for Rare Rx

- Rare diseases market expected to grow 11+% to 2024[3]
- By 2024 rare disease products expected ~18% ℞ sales[4]
- FDA have approved 23 gene/cell therapies to date[5]
- >50% of FDA approvals in 2021 were orphan drugs[6]

Stakeholder Pressure to Act

- Regulatory/payor scrutiny raises standards for approval, access and entry
- Patient engagement for new RD, NDD & gene therapies; even with premium priced products
- Stratification and patient profiling can improve labelling, pricing optimization and success

1 Compare Centogene 20-F for FY2021 p. 56 I 2 CENTOGENE Biodatabank statistic per Dec 31, 2021. I 2 The Scientist (2019) "Lack of Diversity in Genetic Datasets is Risky for Treating Disease", reflecting distribution of ancestry of individuals in genome-wide association studies (GWAS) as of January 2019 I * Statements reflect internal management estimates. I 3 & 4 EvaluatePharma – Orphan Drug Report 2020 p. 2 I 5 Based on FDA approvals per May 2022. [Approved Cellular and Gene Therapy Products | FDA] I 6 EvaluatePharma – Orphan Drug Report 2022 p. 2

Near-term opportunities in addressing key stakeholder challenges

Largest Real-World Data Repository for Rare and Neurodegenerative Diseases



7 Metrics per March 31, 2022. Active Physicians defined as contact with CENTOGENE within the last 5 years, respectively.

First-in-class Data Capture and Proprietary Curation and Analysis Technologies

Data capture

Gold standard for DNA and multiomic sampling
(from >120 countries

All common forms of sampling accepted
(incl. buccal swab)

Clinical data capture



Clinical data extraction & curation

Whole genome sequencing

State-of-the-art mass spectrometry

RNA sequencing

Data bioinformatics

CENTOGENE BIODATABANK



Automated pipelines for

- variant annotation
- prioritization
- medical reporting
- > 31 million variants
- multiomic analysis and combination expertise

Data utilization

Clinical Diagnostics

Biopharma Partnerships

Target & Drug Screening

Clinical Development Support

Market Access & Expansion

Value chain supported by advanced bioinformatics and AI tools

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Leading, Differentiated Core Products Driving Definitive Diagnosis

LAUNCHED JUNE 2021

CentoXome®

LAUNCH March 2022

MOx

≥ 98% of the exome at ≥ 20x

~20,000 genes

~8,000
clinical genes

Non-coding pathogenic variants

HGMD® ClinVar

CENTOGENE

Mitochondrial genome

37 genes

CentoGenome

LAUNCH March 2022

MOx

≥ 97% of the genome at ≥10x

>20,000 genes

Complete genome map in
1 single test

Coding and non-coding regions

Mitochondrial genome

37 genes

CentoMetabolic MOx

≥ 99.5% targeted regions covered at ≥ 20x

206 genes

180
Inherited metabolic disorders

Clinically relevant variants

HGMD®

CENTOGENE

20 enzymes and biomarkers

NGS Panels

≥ 99% targeted regions covered at ≥ 20x

16
disease categories

Single Nucleotide Variants

HGMD®

CENTOGENE

Mitochondrial genome

Auxiliary assays

NGS: Next Generation Sequencing

Unique Pharma Offering

Target & Drug Screening

- Patient-derived Cell Models & Multiomics
- Biomarker/Assay Identification & Validation

Clinical Development

Observational Studies

- Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III

- Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker
- Patient Identification & Diagnostics

Market Access & Expansion

- RW Registry & Early Access Programs
- Patient Stratification, Genetic & Biomarker Profiling, Modelling
- Patient ID & Diagnostics

CENTOGENE Biodata Network

- Insight Reports (e.g., new and existing reports, clinical, genetic, epidemiology)
- Biodata Licenses

Insilico Medicine · evotec · DENALI THERAPEUTICS · alector · agios · Takeda · Pfizer · PTC THERAPEUTICS

Accelerating and De-risking Clinical Programmes

Clinical Development

Observational studies
- Epidemiology & patient finding
- Genetic & biomarker profiling

POC/Ph II/III
- Patient multiomic profiling
- Stratification, Modelling, and Efficacy markers
- Patient identification & diagnostics

CENTOGENE Biodata Network
- Insight Reports & Biodata Licenses

ALEXION AstraZeneca Rare Disease

Hypophosphatasia (HPP)

DENALI THERAPEUTICS

Parkinson's disease (PD)

Takeda

Gaucher disease

agios

Pyruvate kinase ("PK") deficiency

Alnylam PHARMACEUTICALS

Hereditary transthyretin-related amyloidosis (hATTR)

alector

Frontotemporal dementia (FTD)

Maximize Access and Personalize Patient, Provider and Biopharma Value

Market Access and Expansion

- Real world registry
- Early access programs

- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling

- Patient Identification
- Patient Diagnostics

- CENTOGENE Biodata Network
  - Insight Reports & Biodata Licenses

Takeda Shire

Rare Metabolic and Rare Neurodegenerative Diseases

SAREPTA THERAPEUTICS

Duchenne muscular dystrophy (DMD)

Pfizer ATTR INFORMED
Genetic testing and counseling for ATTR-CM

Hereditary transthyretin amyloidosis (hATTR) disease

PTC THERAPEUTICS REVEAL-CP™

DMD & Aromatic L-amino Acid Decarboxylase (AADC)

Near and Mid Term Priorities

Topline

Growth

- Focus on unique and transformative business model
- Expand pharma partnerships
  - Fully execute on our existing >20 ongoing partnerships and target ~20+ new pipeline deals
- Keep growing Dx at above-market level
  - Focus on profitable growth
  - Commercial excellence, CentoCloud & multiomics

2022 Guidance:*

Revenues

~50-52 € million

+15-20% YoY

Bottomline

Cost management

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

Q1 2022

€ 10.3M up +3% yoy acceleration in 2H22 driven by biopharma

Runway

Cashflow

- Sector is not about growth at all costs
- Diligently manage cash and extend runway

$62M financing (~€55M) in Q1 2022: €15M PIPE & $45M secured debt facility **

* Revenues reflect the Diagnostics and Pharma reporting segments, and do not include the COVID-19 Testing revenues recorded in the period 2020 – Q1 2022. COVID-19 Testing has been reported as discontinued operations since Q1 2022. Guidance as communicated per Q1 2022 earnings announcement. ** CENTOGENE announced the closing of a € 15 million (~$ 17 million) private placement financing incl. warrants as well as the entry into a USD 45 million senior secured loan facility on February 1, 2022. / Image source: flaticon.com

CENTOGENE
THE RARE DISEASE COMPANY

Thank you